VP, DM1 Commercial Asset Lead
DYNE Therapeutics - Waltham, MA
Posted Jun 17, 2026
Benefits
- Parental leave
- Not verified
- Non-birth-parent leave
- Not verified
- Family-building benefits
-
- Fertility benefits: Not verified
- Adoption assistance: Not verified
- Surrogacy assistance: Not verified
- Mental health support
- Not verified
- Relocation assistance
- Not verified
- Childcare support
- Not verified
- Learning budget
- Not verified
- Verification
- Not verified checked Nov 20, 2026
- Salary
- $272K-$340K From the posting source checked Nov 19, 2026
- 401(k) match
- Reported from DOL Form 5500 industry filing (not employer-specific)
Was this benefit information wrong? Tell us.
Role
- Seniority
- Director Plus From the posting source checked Nov 19, 2026
Schedule
- Shift type
- Not verified
- Weekend work
- Not verified
Company
- Equity
- Offered Verified - SEC 10-K source checked Nov 19, 2026
Application
- Cover letter
- Not verified
- Assessment
- Not verified
- Deadline
- Not stated
Where they hire
State eligibility is not yet verified.
About this role
VP, DM1 Commercial Asset Lead Waltham, MA Company Overview: Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD), Pompe disease and multiple DMD mutations. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at https://www.dyne-tx.com/ , and follow us on X , LinkedIn and Facebook . Role Summary: The VP, DM1 Commercial Asset Lead (CAL) is a passionate driver of the value of Dyne's DM1 commercial asset with a global perspective, bringing adaptable leadership to develop and implement commercialization strategies that maximize reach and value creation within the neuromuscular portfolio. This mandate includes market analysis, competitive positioning, launch readiness and execution, and input into lifecycle management to support long-term success in bringing the asset to patients globally. The CAL is a highly visible leadership role and, as a key member of the Program Team, works cross-functionally to influence and help shape Program strategy. The CAL leads the definition of commercialization strategy, strategic imperatives, critical success factors, executional priorities, and global launch planning in close partnership with affiliate launch teams. This role balances a forward-looking orientation toward broad global access for patients with a pragmatic approach to planning,
Read the full description at job-boards.greenhouse.io. FewerJobs shows a preview and links to the original posting.
Apply link verified; last checked Nov 20, 2026.
What verified means
Verified means a displayed claim has field-level provenance to a source FewerJobs pulled: a government or employer source, or the original job posting. Posting-sourced facts are employer-stated and are labeled separately from government records.
Related jobs
Director, Medical Review
DYNE Therapeutics - Waltham, MA
Director, REMS Strategy & Operations
Cytokinetics Inc - Radnor, Pennsylvania
Senior Director, Global Market Access
Cogent Biosciences Inc - Waltham, Massachusetts, United States
Vice President, CMC Strategy
Amylyx Pharmaceuticals Inc - Cambridge, MA